Valuation: PTC Therapeutics, Inc.

Market Cap 5.32B 4.75B 4.43B 4.02B 7.58B 514B 7.64B 53.19B 20.76B 262B 19.96B 19.53B 840B P/E 2026 *
41.3x
P/E 2027 * 24.9x
Enterprise Value 3.45B 3.08B 2.87B 2.61B 4.91B 333B 4.95B 34.47B 13.45B 169B 12.93B 12.65B 545B EV / Sales 2026 *
2.74x
EV / Sales 2027 * 2.3x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2023-03-21
Director of Finance/CFO 41 2023-07-12
Chief Tech/Sci/R&D Officer - 2017-09-30
Director TitleAgeSince
Chairman 74 2004-10-31
Chairman 80 1998-03-30
Director/Board Member 65 2005-11-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 5.32B
+2.70%+0.35%+40.67%+110.31% 1,032B
+1.44%-3.41%+37.36%+63.95% 614B
+1.75%+3.07%+17.89%+83.05% 471B
+0.60%-4.35%+60.80%+37.46% 350B
+2.92%+3.06%+24.83%+45.10% 337B
+2.42%-0.74%+13.44%+35.80% 268B
+1.86%-0.81%-4.69%+12.20% 246B
+2.60%-2.49%+40.45%+54.44% 218B
+1.82%-2.93%+29.29%+96.48% 179B
Average +1.81%-3.39%+28.89%+59.87% 412.76B
Weighted average by Cap. +2.07%-3.18%+32.16%+70.59%

Financials

2026 *2027 *
Net sales 1.26B 1.12B 1.05B 952M 1.79B 122B 1.81B 12.58B 4.91B 61.88B 4.72B 4.62B 199B 1.38B 1.23B 1.15B 1.04B 1.96B 133B 1.98B 13.78B 5.38B 67.73B 5.17B 5.06B 218B
Net income 145M 130M 121M 110M 207M 14.07B 209M 1.45B 568M 7.15B 546M 534M 22.98B 218M 195M 182M 165M 311M 21.13B 314M 2.18B 853M 10.74B 820M 802M 34.51B
Net Debt -1.87B -1.67B -1.56B -1.42B -2.67B -181B -2.69B -18.72B -7.31B -92.05B -7.02B -6.87B -296B -2.15B -1.92B -1.79B -1.62B -3.06B -208B -3.08B -21.47B -8.38B -106B -8.05B -7.88B -339B
Projected Income Statement - Annual - PTC Therapeutics, Inc.
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - PTC Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
63.23USD
Average target price
101.79USD
Spread / Average Target
+60.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - PTC Therapeutics, Inc.